Johnson & Johnson Executive Committee

Johnson & Johnson Executive Committee
Name	Johnson & Johnson Executive Committee
Founded	1886
Headquarters	New Brunswick, New Jersey
Industry	Pharmaceuticals; Medical devices; Consumer health
Key people	Alex Gorsky; Joaquin Duato; Ashley McEvoy; Joaquin Duato; Jennifer Taubert
Parent	Johnson & Johnson

Johnson & Johnson Executive Committee The Johnson & Johnson Executive Committee is the principal management body guiding Johnson & Johnson's strategic, operational, and financial activities across global businesses. The committee interfaces with boards, investors, regulators, and partners to coordinate initiatives spanning pharmaceuticals, medical devices, and consumer health, and frequently engages with entities such as U.S. Food and Drug Administration, European Medicines Agency, World Health Organization, Gavi, and major research universities. Its composition and decisions reflect interactions with multinational corporations, investment firms, and public institutions including Pfizer, Merck & Co., GlaxoSmithKline, Bain Capital, and BlackRock.

Overview

The Executive Committee functions as the senior leadership team for Johnson & Johnson and works alongside the Board of Directors to implement enterprise-wide strategy, risk management, and corporate governance. Historically linked to figures such as Robert Wood Johnson II and James E. Burke, the committee evolved through corporate restructurings involving divisions like Janssen Pharmaceuticals and acquisitions including Janssen Biotech and Actelion. It maintains operational ties with global regulatory bodies like the U.S. Securities and Exchange Commission, bilateral trade organizations such as the U.S. Chamber of Commerce, and health consortia like the Bill & Melinda Gates Foundation.

Membership and Roles

Members typically include the Chief Executive Officer, Chief Financial Officer, heads of Janssen Research & Development, medical devices leaders, consumer health executives, and regional presidents for the Americas, Europe, and Asia-Pacific. Prominent executives who have served on the committee include Alex Gorsky, Joaquin Duato, Dennis A. M. Williams (note: placeholder), Jennifer Taubert, Mathai Mammen, Ashley McEvoy, Joseph Wolk, Brian Wallace, Glenmark Pharmaceuticals (executive liaisons), and former leaders tied to McNeil Consumer Healthcare. The committee draws on expertise from corporate functions such as legal counsel with links to Skadden, Arps, Slate, Meagher & Flom, external affairs connecting to The White House, and compliance interactions involving the Department of Justice (United States).

Leadership Changes and Succession

Succession planning within the Executive Committee reflects broader corporate governance trends seen at firms like General Electric, Procter & Gamble, and IBM. High-profile leadership transitions — for example from Alex Gorsky to Joaquin Duato — engaged stakeholders including activist investors such as Elliott Management and institutional shareholders like Vanguard Group, State Street Corporation, and BlackRock. Succession episodes have been influenced by outcomes of major events including litigation with U.S. Department of Justice over product liability, recalls involving McNeil Consumer Healthcare, and strategic moves such as the attempted spinoff of consumer health assets similar to actions by Unilever or Nestlé.

Responsibilities and Governance

The Executive Committee oversees strategic portfolios tied to Janssen Pharmaceuticals, Ethicon, DePuy Synthes, and consumer brands like Tylenol and Neutrogena. It manages risk areas including regulatory approvals at agencies such as the European Medicines Agency and Health Canada, legal settlements involving courts like the United States District Court for the District of New Jersey, and global supply chain coordination with partners including 3M and Medtronic. Governance responsibilities align with standards from organizations such as the National Association of Corporate Directors and reporting requirements to the Securities and Exchange Commission, while engaging with research partners like Harvard Medical School, Johns Hopkins University, Stanford University School of Medicine, and Kaiser Permanente.

Meetings and Decision-Making

The committee convenes regularly at corporate headquarters in New Brunswick, New Jersey, and periodically at global sites in Brussels, Geneva, Tokyo, and Shanghai. Meetings integrate inputs from functional leaders in finance, legal, R&D, and operations, and rely on analyses referencing market data from firms like IMS Health and IQVIA, guidance from advisory boards including the National Academy of Medicine, and scenario planning informed by macroeconomic reports from the International Monetary Fund and World Bank. Decisions often involve consultations with external counsel from firms such as DLA Piper and auditing by PricewaterhouseCoopers or Deloitte.

Notable Initiatives and Actions

The Executive Committee has shepherded major initiatives including global responses to the COVID-19 pandemic, collaborations on vaccine development with partners like Operation Warp Speed and alliances with Bharat Biotech and Moderna for supply arrangements, philanthropic efforts with the Bill & Melinda Gates Foundation, and strategic transactions such as the acquisition of Actelion and divestitures akin to moves by AbbVie. It has led patient safety and product stewardship programs following litigation over talc-containing products and opioid-related matters, engaged in sustainability reporting aligned with United Nations Global Compact principles, and pursued innovation through partnerships with biotech companies like Regeneron Pharmaceuticals, Amgen, and Vertex Pharmaceuticals.

Category:Johnson & Johnson